Earlier Monday, the U.S. FDA approved Bausch + Lomb's (BlCO) eye surgery product, the Teneo Excimer Laser Platform, to conduct a surgical procedure called keratomileusis (LASIK).

Bausch + Lomb sells contact lenses, eye drops and other products that generate a steady revenue stream. Bausch Health’s main drug, the gut antibiotic Xifaxan, will likely face generic competition in ...

Papa took over as the new CEO of Bausch & Lomb, and oversaw the $2.5bn acquisition of the dry eye disease therapy XIIDRA and other ophthalmology assets from Swiss Pharma giant Novartis AG (NVS ...

Emergent appoints former Bausch + Lomb CEO to head company February 21, 2024 The U.S. Food and Drug Administration (FDA) on Wednesday warned consumers not to use unapproved eye drops that closely ...

Elios Vision former chairman and CEO Elliot Friedman said: “Bausch + Lomb’s extensive reach in cataract surgery will introduce ELIOS to a broader range of eye care professionals and help ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that an ...

Bausch + Lomb has a fifty-two week low of $13.16 and a fifty-two week ... and contact lens care products comprising ...

Meet the new Valeant: Drugmaker drops tainted name to become Bausch Health in July rebrand A buyout would be one of the largest private equity healthcare deals of the year as Bausch + Lomb has an ...

Learn more about whether Bausch + Lomb Corporation or Omnicell, Inc. is a better investment based on AAII's A+ Investor ...

Bausch + Lomb sells contact lenses, eye drops and other products that generate a steady revenue stream. Bausch Health’s main drug, the gut antibiotic Xifaxan, will likely face generic ...